Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients
Status:
Recruiting
Trial end date:
2026-07-07
Target enrollment:
Participant gender:
Summary
The current standard of care for locally advanced non-small cell lung cancer (NSCLC) is
concurrent chemoradiation and consolidation immunotherapy. In real world clinical practice,
patients who cannot tolerate concurrent chemoradiation generally received radiotherapy alone
or sequential chemoradiation. These patients are more likely to develop distant metastases
and therefore may require tolerable systemic consolidation regimens. However, there is a lack
of evidence from clinical studies on consolidation immunotherapy after radiotherapy alone or
sequential chemoradiation. The aim of the study is to explore the efficacy and safety of
Tislelizumab consolidation therapy after radiotherapy or sequential chemoradiation in locally
advanced NSCLC patients who are intolerable of concurrent concurrent chemoradiation.